IL17A and Alzheimer disease: Importantly, several pathways dysregulated in AD were also upregulated in our dataset, including IL-5, IL-23, IL-17, and Jak-Stat signaling pathways (Figure 2B), noteworthy because many of these pathways are presently under clinical investigation for the treatment of AD (Paller et al., 2017).